Abstract
The overarching issue with this case study is poor regulation and quality control over direct-to-consumer genetic testing, delivered in the absence of any medical oversight.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Commonwealth of Australia. 2003. Disability Discrimination Act 1992. ACT: Australian Government Publishing Service. http://www.austlii.edu.au/au/legis/cth/consol_act/dda1992264/. Accessed August 7, 2017.
Cruchaga, C., G. Haller, S. Chakraverty, et al. 2012. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS One 7(2): e31039.
Kauwe, J.S., S. Jacquart, S. Chakraverty, et al. 2007. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer’s disease presenilin 1 mutation. Annals of Neurology 61(5): 446–453.
Lacaze, P., R. Woods, S. Zoungas, and J. McNeil. 2017a. The genomic potential of the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies. The International Medical Journal 47(4): 461–463.
Lacaze, P., J. Ryan, R. Woods, I. Winship, and J. McNeil. 2017b. Pathogenic variants in the healthy elderly: Unique ethical and practical challenges. Journal of Medical Ethics 43(10): 714–722.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lacaze, P., Tiller, J. & Ryan, J. The Dangers of Direct-to-Consumer Genetic Testing for Alzheimer’s Disease . Bioethical Inquiry 14, 585–587 (2017). https://doi.org/10.1007/s11673-017-9817-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11673-017-9817-6